• KOSPI 2697.67 -22.97 -0.84%
  • KOSDAQ 734.35 -1.94 -0.26%
  • KOSPI200 359.62 -3.46 -0.95%
  • USD/KRW 1381 -7.00 0.51%
GC Cell's AB-101 NK therapy achieves FDA fast-track status
Bio & Pharma

GC Cell's AB-101 NK therapy achieves FDA fast-track status

AB-101 is currently undergoing phase 1 and 2 clinical trials for patients with recurrent and intractable B-cell non-Hodgkin lymphoma

By

Feb 02, 2023 (Gmt+09:00)

1 Min read
News+
GC Cell's AB-101 NK therapy achieves FDA fast-track status 


South Korea's bio firm GC Cell announced on Wednesday that its US affiliate Artiva Biotherapeutics has received fast-track designation from the US Food and Drug Administration (FDA) for its natural killer (NK) cell therapy candidate AB-101.


AB-101 is a cord blood-derived treatment aimed at harnessing the body's immune system to fight cancer. GC Cell transferred the technology for this product to Artiva.

The treatment is currently undergoing phase 1 and 2 clinical trials for patients with recurrent and intractable B-cell non-Hodgkin lymphoma, including those who have failed to respond to chimeric antigen receptor T cell (CAR-T) treatment.

The FDA's fast-track designation is given to drugs that show potential for excellent efficacy against life-threatening diseases and are in need of quick development.

GC Cell, which was created through the merger of GC Green Cross Lab Cell and GC Green Cross Cell, is a corporation focused on the development and production of treatments using immune cells and stem cells.

Write to Jeong Min Nam at peux@hankyung.com
More To Read
Comment

0/300